The funding will be available to members of the Association of Community Cancer Centers, a cancer care provider advocacy group.

CMS will reimburse FoundationOne CDx at a rate of $3,500 per test for a nine-month period starting July 1.

The group will combine VIB's sequencing technology with Verge's machine learning platform to study banked tissue samples at UCSD in a drug discovery effort.

The NGS-based test improves on a previous PCR-based version and detects circulating DNA from Epstein Barr virus that is shed from cancer cells.

Researchers described diet-related patterns of gut microbial diversity, microbiome ties to psychiatric disease, and more.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.

The BD Rhapsody Single-Cell Analysis System empowers and streamlines single-cell research with a complete system of tools, including reagents and analysis software, that work together to meet neuroscience experimental needs. Neuroscientists’ ability to identify and characterize individual cells in the nervous system opens the door to finding pathogenic cells, regenerative cells, and pathways that drug manufacturers can exploit for the discovery of therapeutics for neurodegenerative disease.

As the field of therapeutic antibody research expands, scientists face a growing need for software that enables them to efficiently and accurately analyze their data. Highly functional bioinformatics software solutions significantly reduce the need to manually curate sequence data or convert it into different formats for sharing and archiving. Unfortunately, there are currently few specialist antibody screening and analysis platforms that can be quickly configured to meet the highly custom needs of specialized therapeutic antibody discovery organizations.

Highly predictive patient-derived xenograft (PDX) models can predict clinical efficacy for oncology drug candidates better than traditional cell line-derived preclinical models. This white paper describes how PDX models can be used in Mouse Clinical Trials, upending the traditional paradigm in animal studies and providing a better perspective of patient-to-patient heterogeneity.